<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173208</url>
  </required_header>
  <id_info>
    <org_study_id>MT-SECFLOR</org_study_id>
    <nct_id>NCT04173208</nct_id>
  </id_info>
  <brief_title>Main Trial of the Cesarean Section and Intestinal Flora of the Newborn Study</brief_title>
  <acronym>MT-SECFLOR</acronym>
  <official_title>Main Trial of the Cesarean Section and Intestinal Flora of the Newborn Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators assess whether, in CS-delivered infants, the intestinal
      microbiome could be successfully and safely normalised by postnatal oral transfer of maternal
      fecal microbiome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the investigators assess whether, in CS-delivered infants, the intestinal
      microbiome could be successfully and safely normalised by postnatal oral transfer of maternal
      fecal microbiome. After faecal microbiota transfer, the children are followed for 24 months
      for the evaluation of markers of, for example, atopy-related diseases, and changes in
      immunomarkers associated with the transfer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Longitudinal change of intestinal microbiota assessed with 16S rRNA and shotgun sequencing</measure>
    <time_frame>At three months of age</time_frame>
    <description>Developmental trajectory of the intestinal microbiota, assessed with 16s rRNA gene amplicon and shotgun sequencing of fecal DNA to determine the changes in the intestinal microbiota composition, diversity and functionality from birth to three months of age</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in markers of cow milk immunoglobulin Es</measure>
    <time_frame>At 12 months of age</time_frame>
    <description>The difference in markers of allergen-specific immunoglobulin Es between the intervention group and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in markers of aeroallergen immunoglobulin Es</measure>
    <time_frame>At 24 months of age</time_frame>
    <description>The difference in markers of allergen-specific immunoglobulin Es between the intervention group and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in tetanus and measles, mumps and rubella vaccine responses</measure>
    <time_frame>At 12 and 24 months of age</time_frame>
    <description>The difference in vaccine responses between the intervention group and the placebo group (as Immunoglobulin G milli-International Units/milliliter).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal change of intestinal microbiota assessed with 16S rRNA and shotgun sequencing</measure>
    <time_frame>At 6, 12 and 24 months of age</time_frame>
    <description>Developmental trajectory of the intestinal microbiota, assessed with 16s rRNA gene amplicon and shotgun sequencing of fecal DNA to determine the changes in the intestinal microbiota composition, diversity and functionality from birth to three months of age</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Differences in immunoresponse to the transplant</measure>
    <time_frame>At 3 days and 3, 6, 12 and 24 months of age</time_frame>
    <description>The differences in immunomarkers between the intervention group and the placebo group (measured by performing messenger ribonucleic acid sequencing of viable peripheral blood mononuclear cells).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Fecal Microbiota Transplantation</condition>
  <condition>Cesarean Section, Affecting Fetus or Newborn</condition>
  <condition>Intestinal Microbiome</condition>
  <arm_group>
    <arm_group_label>Fecal microbial transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants of the experimental arm will receive an oral fecal microbial transplant after delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The participants of the placebo arm will receive an oral placebo after delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal microbial transplant</intervention_name>
    <description>Fecal microbial transplant</description>
    <arm_group_label>Fecal microbial transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-eventful pregnancy

          -  planned elective CS

          -  Finnish language competency

        Exclusion Criteria:

        Mother:

          -  maternal refusal

          -  positive findings in screening samples

          -  maternal antibiotic treatment within 4 weeks of delivery (excluding the antibiotic
             given immediately prior to clamping of the umbilical cord)

          -  travel outside European Union during 3 months prior to delivery

          -  CS after the onset of labor (non-elective CS)

        Newborn:

          -  birth below 37 weeks of gestation

          -  Apgar score of less than 8

          -  disturbances of neonatal adaptation (such as transient tachypnea of the newborn)

          -  antibiotic treatment of the newborn before discharge
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnancy</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Otto Helve, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital, Helsinki University Hospital and the University of Helsinki</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Otto Helve, MD, PhD</last_name>
    <phone>35894711</phone>
    <email>Otto.helve@helsinki.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital, Helsinki University Hospital, Pediatric Research Center</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otto Helve, Adj. prof</last_name>
      <phone>+358505824426</phone>
      <email>otto.helve@helsinki.fi</email>
    </contact>
    <contact_backup>
      <last_name>Sture Andersson, Prof</last_name>
      <phone>+35894711</phone>
      <email>sture.andersson@hus.fi</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Otto Helve</investigator_full_name>
    <investigator_title>Adjunct professor</investigator_title>
  </responsible_party>
  <keyword>Transplant</keyword>
  <keyword>Cesarean section</keyword>
  <keyword>inflammatory response</keyword>
  <keyword>Infant</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

